Filtering by:
Targeted Therapy2019 in Review: New Cancer Drug Approvals
In 2019, the FDA approved several new drug treatments for different cancer types. Here are the stories that made headlines on cancer.org this year.
Cancer Patients May Not Be Told About Costs of Genomic Testing
As of 2016, more than 200 targeted therapies (also called precision medicines) were available in the United States, and more than 2,000 were in the last stages of development—half of them to treat cancer. For many of these drugs, doctors first use genomic testing of the cancer cells to get an idea of whether the treatment will work. Yet, nearly 1 in 4 oncologists rarely or never mention costs when they talk about the need for genomic testing with their cancer patients, according to a new study led by American Cancer Society (ACS) investigators.
FDA Approves Rozlytrek (Entrectinib) for Tumors With Certain Genetic Markers
The US Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for adults and adolescents with tumors that test positive for NTRK gene changes, which can help cancerous tumors grow.
FDA Approves Polivy (Polatuzumab Vedotin-piiq) for Lymphoma
The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) to treat people with diffuse large B-cell lymphoma (DLBCL).
FDA Approves First PI3K Inhibitor for Breast Cancer
The US Food and Drug Administration (FDA) has approved the first treatment of its kind for a certain type of breast cancer caused by an inherited genetic mutation. Piqray (alpelisib) is a targeted therapy called a PI3K inhibitor.
FDA Approves First Targeted Therapy for Bladder Cancer
The US Food and Drug Administration (FDA) has approved Balversa (erdafitinib) as the first targeted therapy for bladder cancer.
2018 in Review: New Cancer Drug Approvals
In 2018, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
New Drug Reduces Recurrence Risk for Some Women With Early-Stage Breast Cancer
Research presented at the San Antonio Breast Cancer Symposium may result in a new standard of care for some people with HER2 positive, early stage breast cancer.
